An ERRα/γ agonist that mimics the metabolic effects of endurance exercise at the molecular level.
SLU-PP-332 is a small molecule agonist of estrogen-related receptors alpha and gamma (ERRalpha/gamma), developed by researchers at Washington University in St. Louis. It activates the same transcriptional programs as endurance exercise, promoting mitochondrial biogenesis, fatty acid oxidation, and metabolic adaptation — essentially acting as an exercise mimetic at the molecular level. A landmark 2023 study published in the Journal of Pharmacology and Experimental Therapeutics demonstrated that SLU-PP-332 improved exercise capacity, reduced fat mass, and enhanced metabolic function in obese mice without changes in food intake. The compound is of significant interest as a potential treatment for obesity, metabolic syndrome, and conditions where exercise capacity is limited. Unlike stimulants or appetite suppressants, SLU-PP-332 works by reprogramming cellular metabolism at the transcriptional level, creating lasting changes in how cells process and utilize energy. It is particularly notable for its ability to increase the proportion of oxidative (slow-twitch) muscle fibers, which are more metabolically active and fatigue-resistant.
“An ERRα/γ agonist that mimics the metabolic effects of endurance exercise at the molecular level.”
SLU-PP-332 binds to and activates ERRalpha and ERRgamma, orphan nuclear receptors that function as master regulators of mitochondrial biogenesis and oxidative metabolism. These receptors control the expression of hundreds of genes involved in mitochondrial biogenesis (PGC-1alpha, TFAM), oxidative phosphorylation (all five electron transport chain complexes), fatty acid oxidation (CPT1, HADHA), and glucose metabolism. Activation of ERRalpha/gamma by SLU-PP-332 mimics the gene expression changes induced by endurance exercise training, including increased mitochondrial density, enhanced fat oxidation capacity, and improved insulin sensitivity. The compound also promotes fiber type switching in skeletal muscle, increasing the proportion of type I (slow-twitch, oxidative) fibers that are more metabolically active. These transcriptional changes persist after the compound is cleared, potentially providing lasting metabolic benefits similar to the adaptations achieved through regular endurance exercise.
When sourcing SLU-PP-332 (Capsule) for research purposes, the following quality benchmarks should be verified before use.
>98% (verified by HPLC)
Must be provided by supplier
<0.1 EU/mg (prevents bacterial contamination)
Manufactured in cGMP-certified facility
Independent lab verification preferred
Store at room temperature, away from light and moisture.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Early-stage research only. Significant uncertainty about efficacy and safety in humans.
Animal & In-Vitro Only — Mechanism observed in cell culture or animal models. No human efficacy data. Not evidence of an effect in humans.
Peptides commonly used alongside SLU-PP-332 (Capsule) for synergistic effects.
Category
Status
Dose
Frequency
Cycle
Peptides
Protocols
Other Pages
Contact Us Today!
© 2026 Best Health IQ. All rights reserved.
FDA Disclaimer: The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many compounds described on this site are not approved by the FDA for human therapeutic use. Some are available only as compounded preparations or as materials sold for laboratory use, and several are on FDA's Category 2 list for significant safety risks. Nothing on this site constitutes medical advice or a recommendation to use any compound described.
